作为降脂试验结果衡量指标的相对风险降低率与需治疗人数
Relative risk reduction versus number needed to treat as measures of lipid-lowering trial results.
作者信息
Moriarty P M
出版信息
Am J Cardiol. 1998 Aug 15;82(4):505-7. doi: 10.1016/s0002-9149(98)00367-1.
PMID:9723640
Abstract
Recent clinical trials dealing with cholesterol reduction in primary and secondary prevention for cardiovascular disease use Relative Risk Reduction to assess their clinical outcomes. Number Needed to Treat is a more valid measurement.
摘要
近期关于心血管疾病一级和二级预防中降低胆固醇的临床试验使用相对风险降低率来评估其临床结果。需治疗人数是一种更有效的衡量指标。
相似文献
1
Relative risk reduction versus number needed to treat as measures of lipid-lowering trial results.作为降脂试验结果衡量指标的相对风险降低率与需治疗人数
Am J Cardiol. 1998 Aug 15;82(4):505-7. doi: 10.1016/s0002-9149(98)00367-1.
2
Should separate endpoint trials be required for all lipid-lowering drugs acting by the same mechanism?
Am J Cardiol. 1998 Apr 23;81(8A):88F-94F.
3
Clinical trial assessment of lipid-acting drugs in diabetic patients.糖尿病患者中脂质作用药物的临床试验评估。
Am J Cardiol. 1998 Apr 23;81(8A):58F-59F. doi: 10.1016/s0002-9149(98)00265-3.
4
Primary prevention of ischaemic heart disease with lipid-lowering drugs.使用降脂药物对缺血性心脏病进行一级预防。
Lancet. 1988 Feb 13;1(8581):333-4.
5
Inclusion of lipoprotein subfractions among efficacy parameters.将脂蛋白亚组分纳入疗效参数之中。
Am J Cardiol. 1998 Apr 23;81(8A):52F-55F. doi: 10.1016/s0002-9149(98)00263-x.
6
Clinical trials: Evidence and unanswered questions--hyperlipidaemia.临床试验：证据与未解决的问题——高脂血症
Cerebrovasc Dis. 2003;16 Suppl 3:25-32. doi: 10.1159/000070274.
7
Hyperlipidaemia and cardiovascular disease.高脂血症与心血管疾病。
Curr Opin Lipidol. 2001 Dec;12(6):667-9. doi: 10.1097/00041433-200112000-00011.
8
Effects of lipid lowering on coronary plaques and coronary events.
Am J Cardiol. 1997 Oct 30;80(8B):8H-9H.
9
New evidence in hypertension and hyperlipidaemia.高血压和高脂血症的新证据。
Heart. 2004 Jun;90 Suppl 4(Suppl 4):iv14-7. doi: 10.1136/hrt.2004.037556.
10
Prevention of cardiovascular events by hypolipidemic therapy evidence-based medicine criteria.通过降血脂治疗预防心血管事件：循证医学标准
Acta Clin Belg. 1999 Oct;54(5):299-301. doi: 10.1080/17843286.1999.11754249.
引用本文的文献
1
Cost-effectiveness analysis of n-3 polyunsaturated fatty acids (PUFA) after myocardial infarction: results from Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)-Prevenzione Trial.心肌梗死后n-3多不饱和脂肪酸（PUFA）的成本效益分析：意大利心肌梗死存活研究组（GISSI）-预防试验的结果
Pharmacoeconomics. 2001;19(4):411-20. doi: 10.2165/00019053-200119040-00008.
2
The cost of treating dyslipidaemia using National Cholesterol Education Program (NCEP) guidelines.采用美国国家胆固醇教育计划（NCEP）指南治疗血脂异常的成本。
Pharmacoeconomics. 1998;14 Suppl 3:19-28. doi: 10.2165/00019053-199814003-00003.
Zotero 插件